We are dedicated to advancing pharmaceutical innovation through our expertise in Small Molecule API and API Process Research and Development, and API Characterization. Understanding the intricacies of API crystallinity and polymorphism is crucial for drug efficacy and stability, and we offer specialized services to navigate these complexities.
Note: This service is for research use only and not intended for clinical use.
Overview of API Crystallinity and Polymorphism
Active pharmaceutical ingredient (API) crystallinity refers to the degree of structural order in an active pharmaceutical ingredient. Polymorphism is the ability of an API to exist in multiple crystalline forms, each with distinct physical and chemical properties. These characteristics significantly impact a drug's solubility, bioavailability, stability, and manufacturability. By thoroughly analyzing crystallinity and polymorphism, we help your APIs perform optimally throughout their lifecycle.
Our Services
Polymorphic Characterization
We conduct exhaustive polymorphic screenings to map and characterize all potential crystalline forms of your API, ensuring the selection of the most stable and therapeutically optimal solid-state form. Utilizing advanced techniques such as X-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC), we assess thermodynamic stability, solubility profiles, and phase transition behaviors under varied environmental conditions. Our systematic approach identifies risks of undesired polymorphic shifts during manufacturing or storage, enabling robust process design and intellectual property protection. By prioritizing forms with superior bioavailability and manufacturability, we align outcomes with regulatory expectations for API quality control and lifecycle management.
Crystallinity Characterization
Our crystallinity analysis quantifies the amorphous-to-crystalline ratio within APIs, a critical determinant of dissolution behavior and bioavailability. Leveraging solid-state nuclear magnetic resonance (SSNMR) and Fourier-transform infrared spectroscopy (FTIR), we probe molecular packing arrangements, lattice defects, and crystallite size distribution. These insights guide formulation strategies to enhance solubility for poorly bioavailable compounds or stabilize hygroscopic APIs prone to moisture-induced degradation. By correlating crystallinity with mechanical properties like compressibility and flowability, we support the development of drug products that meet pharmacopeial standards for consistency and performance across manufacturing scales.
Solvate and Hydrate Characterization
We rigorously evaluate solvate and hydrate formation to predict API stability under environmental stressors such as humidity and temperature fluctuations. Using thermogravimetric analysis (TGA) and dynamic vapor sorption (DVS), we detect solvent or water molecules within crystal lattices and analyze their binding stoichiometry and desolvation thresholds. This data informs critical decisions on storage conditions, packaging requirements, and manufacturing controls to prevent phase transitions or solvent retention. By addressing risks of hydrate-mediated instability or solvate-induced batch variability, we ensure compliance with global regulatory standards and maintain product integrity throughout the supply chain.
Applications
- Drug Formulation Optimization: Tailoring API forms for optimal solubility and stability.
- Quality Control: Ensuring consistent API performance through rigorous characterization.
- Process Development: Refining manufacturing processes based on API properties.
- Shelf-life Extension: Enhancing stability to prolong product viability.
- Innovative Therapeutics: Developing novel drug forms for improved outcomes.
Why Choose Us
Expert Team: Our scientists have extensive experience in API characterization and pharmaceutical development.
Customized Solutions: Services tailored to meet your specific project needs.
Timely Results: Commitment to delivering comprehensive reports within agreed timelines.
Frequently Asked Questions
Q1: Why is polymorphism important in API development?
Polymorphism can affect an API's solubility, stability, and bioavailability. Identifying and controlling polymorphic forms ensures consistent drug performance and compliance with regulatory requirements.
Q2: How do crystalline and amorphous forms differ in APIs?
Crystalline forms have an ordered molecular structure, leading to distinct melting points and solubility profiles. Amorphous forms lack this order, often resulting in higher solubility but reduced stability.
Q3: Can co-crystals improve drug solubility?
Yes, co-crystals can enhance solubility and dissolution rates by modifying the crystal lattice without changing the API's chemical identity, improving bioavailability in poorly soluble drugs.